Saltar al contenido
Merck

Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus.

Journal of clinical epidemiology (2013-07-17)
Jason T Connor, Jordan J Elm, Kristine R Broglio
RESUMEN

We present a novel Bayesian adaptive comparative effectiveness trial comparing three treatments for status epilepticus that uses adaptive randomization with potential early stopping. The trial will enroll 720 unique patients in emergency departments and uses a Bayesian adaptive design. The trial design is compared to a trial without adaptive randomization and produces an efficient trial in which a higher proportion of patients are likely to be randomized to the most effective treatment arm while generally using fewer total patients and offers higher power than an analogous trial with fixed randomization when identifying a superior treatment. When one treatment is superior to the other two, the trial design provides better patient care, higher power, and a lower expected sample size.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Piracetam
Supelco
Valproic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Levetiracetam, ≥98% (HPLC)
Sigma-Aldrich
5,5-Diphenylhydantoin, ≥98%
Supelco
Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
2-Propylpentanoic acid
Supelco
Valproic acid solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Phenytoin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Phenytoin, European Pharmacopoeia (EP) Reference Standard
Levetiracetam, European Pharmacopoeia (EP) Reference Standard
Levetiracetam impurity D, European Pharmacopoeia (EP) Reference Standard
Phenytoin for system suitability, European Pharmacopoeia (EP) Reference Standard